Otofarma SpA (MIL:OTO) Research & Development: € Mil (TTM As of Dec. 2024)


MIL:OTO Otofarma SpA MIL:OTO
16 GF Score
Price €2.80
! 1 Warning Sign
View Full Analysis

What is Otofarma SpA Research & Development?

Otofarma SpA MIL:OTO -0.71% 16 Research & Development is € Mil as of Dec. 2024. GuruFocus rates MIL:OTO with a GF Score™ of 16/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Otofarma SpA's Research & Development for the six months ended in Dec. 2024 was €0.00 Mil. Otofarma SpA does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Dec. 2024.

Otofarma SpA  (MIL:OTO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Otofarma SpA Research & Development Related Terms

Otofarma SpA Research & Development Historical Data

* Premium members only.

The historical data trend for Otofarma SpA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Otofarma SpA Research & Development Chart

Otofarma SpA Annual Data
Trend Dec23 Dec24
Research & Development
0.00 0.00

Otofarma SpA Semi-Annual Data
Dec23 Dec24
Research & Development 0.00 0.00
MIL:OTO
16GF Score
Otofarma SpA MIL:OTO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Otofarma SpA Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of € Mil mean?
Otofarma SpA (MIL:OTO) has a Research & Development of € Mil as of Dec. 2024. Research and development expense is the total cost for research and development activities. View historical data on Otofarma SpA and its competitors.
Is Otofarma SpA's Research & Development too high?
Otofarma SpA's current Research & Development is € Mil. Overall, Otofarma SpA has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Otofarma SpA's Research & Development compare to ABT and SYK?
Otofarma SpA's Research & Development of € Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Otofarma SpA and its competitors. Otofarma SpA's current Research & Development is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Otofarma SpA stock overvalued right now?
Otofarma SpA (MIL:OTO) has a current Research & Development of € Mil. The current Research & Development is € Mil. Otofarma SpA's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Otofarma SpA (MIL:OTO), the current Research & Development is € Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Otofarma SpA Business Description

Address Ripuaria Way, 50k, Marina di Varcaturo, Naples, ITA, 80014
Otofarma SpA is engaged in the construction and production of hearing aids, is constantly growing in the audiological field to provide adequate responses to every type of hearing aid need to its customers who require the possible personalized application of custom-made hearing aids. It provides otoacoustic medical devices and TELEMEDICINE services exclusively in affiliated pharmacies, possessing a portfolio of Instrumental IT patents.
16GF Score

Get the complete analysis for MIL:OTO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.80
Price